Keywords : Cataract surgery
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 4, Pages 1420-1424
Aim: The purpose of this study was to determine the safety and effectiveness of a nepafenac punctal plug delivery system (N-PPDS) after cataract surgery.
Methods: The investigation was carried out in a single Indian clinical setting. It is a single-center, randomised, parallel-arm, double-masked, prospective pilot research. Thirty-eight participants (aged 22 and higher) with predicted postcataract correctable distant vision of 20/30 or better and lower puncta enabling dilatation up to 1.0 mm were included in the study (N-PPDS group). All of the eyes had standard unilateral cataract surgery with intraocular lens implantation. Postoperative ocular discomfort and inflammation were used as primary and secondary efficacy measures, respectively.
Results: The experimental N-PPDS group had 38 patients, while the control group included 18 individuals. The N-PPDS group had a substantially greater proportion of pain-free patients (22/32 [69%] after 3 days, P =.038; and 24/36 [67%] at 7 days, P =.018). The N-PPDS group had a larger percentage of pain-free patients (15/29 [52 percent]) at all visits (P =.001). At 7 days, the N-PPDS group had good anterior chamber cell scores (patients with no anterior chamber cells: 18/36 [50%]; P =.034). At 14 days, the plug retention rate was 98 percent (55/56).
Conclusion: Adverse events associated with the punctal plug therapy occurred in 1 case of the N-PPDS group involving placement. The N-PPDS was shown to be both safe and effective in the treatment of ocular discomfort and inflammation following cataract surgery.